Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 130

1.

Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line.

Dulucq S, Etienne G, Morisset S, Klein E, Chollet C, Robbesyn F, Turcq B, Tigaud I, Hayette S, Nicolini FE, Mahon FX.

Ann Hematol. 2019 May;98(5):1159-1168. doi: 10.1007/s00277-019-03633-x. Epub 2019 Feb 23.

PMID:
30798348
2.

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC.

J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29.

3.

Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor.

Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchialla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G.

Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Epub 2016 Apr 1. Review.

PMID:
27131622
4.

BCR-ABL1 Transcript Levels at 3 and 6 Months Are Better for Identifying Chronic Myeloid Leukemia Patients with Poor Outcome in Response to Second-Line Second-Generation Tyrosine Kinase Inhibitors after Imatinib Failure: A Report from a Single Institution.

Ribeiro BF, Vergílio BR, Miranda EC, Almeida MH, Delamain MT, da Silveira RA, de Souza CA, Albuquerque DM, Santos AD, Duarte VO, Oliveira-Duarte GB, Lorand-Metze I, Pagnano KB.

Acta Haematol. 2015;134(4):248-54.

PMID:
26159458
5.

Impact of the BCR-ABL1 fusion transcripts on different responses to Imatinib and disease recurrence in Iranian patients with Chronic Myeloid Leukemia.

Rostami G, Hamid M, Jalaeikhoo H.

Gene. 2017 Sep 5;627:202-206. doi: 10.1016/j.gene.2017.06.018. Epub 2017 Jun 13.

PMID:
28627443
6.

Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance.

Zhang J, Wang Y, Wang J, Hu J, Chen S, Jin J, Liu T, Zhou J, Hu Y, Ma D, Huang X, Ji C, Hou M.

Blood Cancer J. 2018 Jun 15;8(7):61. doi: 10.1038/s41408-018-0093-4.

7.

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib.

Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party.

Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

8.

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia.

Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP.

BMC Cancer. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173.

9.

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP.

Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23.

10.

Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia.

El Missiry M, Hjorth-Hansen H, Richter J, Olson-Strömberg U, Stenke L, Porkka K, Kreutzman A, Mustjoki S.

PLoS One. 2017 Jan 30;12(1):e0171041. doi: 10.1371/journal.pone.0171041. eCollection 2017.

11.
12.

The impact of early molecular response in children and adolescents with chronic myeloid leukemia treated with imatinib: a single-center study from China.

Shao H, Zeng Z, Cen J, Zhang J, Bai S, Wu C, Gong Y, Wang Y, Qiu H, Chen S, Pan J.

Leuk Lymphoma. 2018 Sep;59(9):2152-2158. doi: 10.1080/10428194.2017.1422860. Epub 2018 Jan 15.

PMID:
29334300
13.

Deep molecular responses achieved in chronic myeloid leukemia in chronic phase patients with BCR-ABL1 >10% at 3 months who are early switched to nilotinib.

Yue Y, Gui X, He X, Chen Y, Pan J, Qiu H, Wu D, Chen S, Guo L, Cen J.

Hematology. 2016 May;21(4):213-7. doi: 10.1179/1607845415Y.0000000034. Epub 2015 Jul 17.

PMID:
26183593
14.

Outcomes of Chronic Myeloid Leukemia Patients With Early Molecular Response at 3 and 6 Months: A Comparative Analysis of Generic Imatinib and Glivec.

Eskazan AE, Sadri S, Keskin D, Ayer M, Kantarcioglu B, Demirel N, Aydin D, Aydinli F, Yokus O, Ozunal IE, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T.

Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):804-811. doi: 10.1016/j.clml.2017.07.255. Epub 2017 Aug 4.

PMID:
28847475
15.

Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.

Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H.

Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2.

16.

Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients.

Arun AK, Senthamizhselvi A, Mani S, Vinodhini K, Janet NB, Lakshmi KM, Abraham A, George B, Srivastava A, Srivastava VM, Mathews V, Balasubramanian P.

Int J Lab Hematol. 2017 Jun;39(3):235-242. doi: 10.1111/ijlh.12616. Epub 2016 Dec 29.

PMID:
28035733
17.

Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib.

Hanfstein B, Lauseker M, Hehlmann R, Saussele S, Erben P, Dietz C, Fabarius A, Proetel U, Schnittger S, Haferlach C, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Haematologica. 2014 Sep;99(9):1441-7. doi: 10.3324/haematol.2013.096537. Epub 2014 May 16.

18.

Early landmark analysis of imatinib treatment in CML chronic phase: less than 10% BCR-ABL by FISH at 3 months associated with improved long-term clinical outcome.

Ohm L, Arvidsson I, Barbany G, Hast R, Stenke L.

Am J Hematol. 2012 Aug;87(8):760-5. doi: 10.1002/ajh.23238. Epub 2012 May 28.

19.

Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.

Yin XF, Ma QL, Mu QT, Shao L, Wang SS, Meng HT, Xu WL, Wang YG, Chen ZM, Chen FF, Jin J.

Leuk Res. 2014 Oct;38(10):1191-8. doi: 10.1016/j.leukres.2014.07.003. Epub 2014 Jul 29.

PMID:
25115808
20.

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Pfirrmann M, Evtimova D, Saussele S, Castagnetti F, Cervantes F, Janssen J, Hoffmann VS, Gugliotta G, Hehlmann R, Hochhaus A, Hasford J, Baccarani M.

J Cancer Res Clin Oncol. 2017 May;143(5):843-850. doi: 10.1007/s00432-016-2321-2. Epub 2017 Jan 12.

PMID:
28083711

Supplemental Content

Support Center